Author: Contec Healthcare
Tags:Compounding Pharmacy, USP, Webinar

Strategies for Control of Hazardous Drug Residues

Join industry experts Mark Wiencek and Michael Myers as they provide essential guidance on managing hazardous drug residue, with a focus on NAPRA Model Standards and USP Chapter <800> compliance.
00:0300:05

Webinar Description

 

This webinar will provide essential guidance on managing hazardous drug residue (or referred by NAPRA Model Standards as hazardous contamination), with a focus on NAPRA Model Standards and USP Chapter <800> compliance.

Join industry experts Mark Wiencek and Michael Myers as they share key insights into best practices for contamination control, cleaning protocols, decontamination/deactivation, and regulatory compliance.

You’ll also be able to engage with our Expert Panel: Have your questions answered by leading professionals Aimee Kohler R.Ph.T, Melanie Dorey R.Ph.T, and Jennifer Tuck R.Ph.T in an interactive Q&A session.

Key Takeaways

  • Hazardous drug residues pose significant occupational health risks.
  • Residues can enter and persist in cleanroom environments through multiple pathways.
  • Regulatory guidance from NIOSH, USP <800>, and NAPRA informs control strategies.
  • Effective decontamination requires appropriate chemistries and structured processes.
  • Surface sampling is essential to verify residue reduction.
  • Data-driven decision-making supports ongoing contamination control and compliance.

Featured Presenters

Webinar Section Summaries

Defining Hazardous Drugs and Associated Risks

Hazardous drugs are defined using NIOSH criteria, which identify drugs that may pose health risks with repeated exposure.

 

Key points:

 

  • Based on toxicological properties
  • Include drugs critical for patient care but risky for personnel
  • Updated lists (e.g., 2016 → newer revisions) refine classifications

 

Sources and Pathways of Hazardous Drug Residue

 

Residue can enter the cleanroom through:

 

  • Drug compounding activities
  • Surface contamination
  • Equipment and materials
  • Personnel handling

 

Understanding these pathways is essential for designing effective control strategies.

 

Occupational Exposure and Health Implications

 

Repeated exposure to hazardous drug residue can lead to:

 

  • Long-term health effects
  • Documented occupational risks

 

Residue control is therefore not just a compliance issue—it is a worker safety issue.

 

Regulatory Framework (NIOSH, USP <800>, NAPRA)

 

Multiple regulatory and guidance bodies influence HD residue control:

 

  • NIOSH → Defines hazardous drugs
  • USP <800> → Provides handling and decontamination requirements
  • NAPRA → Offers aligned guidance (especially in Canada)

 

These frameworks guide how facilities manage exposure and contamination.

 

Decontamination Strategies and Chemical Approaches

 

Effective decontamination involves:

 

  • Selecting appropriate chemical agents
  • Using processes designed to neutralize or remove residues
  • Aligning practices with regulatory guidance

 

Not all cleaning agents are effective against hazardous drug residues—specific chemistries are required.

 

Cleaning Processes and Residue Reduction Techniques

 

Residue reduction requires:

 

  • Structured cleaning protocols
  • Consistent application techniques
  • Integration into routine workflows

 

Facilities must go beyond basic cleaning and implement targeted decontamination processes.

 

Measuring Residue: Sampling and Monitoring

 

To determine effectiveness, facilities must measure residue levels through:

 

  • Surface sampling (wipe sampling)
  • Analytical testing methods

 

Measurement provides objective data on contamination levels.

 

Interpreting Results and Ensuring Effectiveness

 

Data from sampling must be used to:

 

  • Evaluate cleaning effectiveness
  • Identify trends or problem areas
  • Drive corrective actions

 

The ultimate goal is to demonstrate successful residue reduction and maintain safe environments.

Behind the Scenes

product
product
product